Adamis Pharmaceuticals Corp (NASDAQ:ADMP) CEO Dennis J. Phd Carlo sold 10,477 shares of the stock in a transaction on Monday, August 19th. The shares were sold at an average price of $1.06, for a total transaction of $11,105.62. Following the transaction, the chief executive officer now owns 353,930 shares in the company, valued at $375,165.80. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
NASDAQ ADMP traded down $0.03 during trading hours on Thursday, reaching $1.05. 5,707 shares of the company traded hands, compared to its average volume of 583,839. Adamis Pharmaceuticals Corp has a 12 month low of $0.93 and a 12 month high of $4.25. The company has a current ratio of 1.04, a quick ratio of 0.79 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $66.35 million, a PE ratio of -1.05 and a beta of 1.28. The company has a 50 day moving average of $1.16 and a two-hundred day moving average of $1.88.
Adamis Pharmaceuticals (NASDAQ:ADMP) last posted its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.03). The company had revenue of $5.77 million for the quarter, compared to the consensus estimate of $5.82 million. Adamis Pharmaceuticals had a negative net margin of 205.32% and a negative return on equity of 86.04%. On average, equities research analysts anticipate that Adamis Pharmaceuticals Corp will post -0.46 earnings per share for the current year.
A number of research analysts have commented on the stock. Raymond James set a $4.00 price objective on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, May 10th. Maxim Group set a $6.00 price objective on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 9th. ValuEngine upgraded shares of Adamis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, August 10th. B. Riley upgraded shares of Adamis Pharmaceuticals from a “sell” rating to a “neutral” rating in a research note on Tuesday, July 23rd. Finally, Dawson James assumed coverage on shares of Adamis Pharmaceuticals in a research note on Tuesday, July 2nd. They set a “buy” rating on the stock. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $3.87.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Further Reading: Hold Rating
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.